Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology September 1, 2023 Guy M. Goodwin, Megan Croal, David Feifel et al. 166 citations
Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect. This phase II, exploratory, international, fixed-dose, open-label study explored the safety,...